Fetal Treatment Program of New England
URL COPIED!
MaterniT21 Plus: DNA-Based Down syndrome test
Currently, our screening tests only allow us to estimate the risk that a fetus may be affected with Down syndrome. While these tests have helped physicians and pregnant women for years, there is now a new, DNA-based screening test. High-risk women now have the option of undergoing a screening test that has a detection rate of greater than 99 percent for Down syndrome with a very low false positive rate. The MaterniT21 Plus test is a simple blood test that examines fetal DNA in maternal blood and can give accurate information to pregnant women about Down syndrome, as well as two other common chromosomal abnormalities, trisomy 18 and trisomy 13. This test is currently only available to high-risk women.
Fetal Treatment Program of New England
- Who We Are
- Why Choose Us
- Our Services
-
Conditions We Treat
- Abdominal Cysts
- Amniotic Band Syndrome
- Bladder Exstrophy
- Cleft Lip and Palate
- Club Foot
- Congenital Diaphragmatic Hernia (CDH)
- Congenital Heart Disease
- Congenital High Airway Obstruction Syndrome (CHAOS)
- Congenital Lung Lesions
- Congenital Tumors
- Congenital Urinary Tract Obstruction
- Craniosynostosis
- Duodenal Atresia
- Esophageal Atresia
- Fetal Arrhythmia/Dysrhythmia
- Gastroschisis
- Hydrocephalus
- Hypoplastic Left and Right Heart Syndrome
- Intestinal Atresia
- Lymphatic and Vascular Malformations
- Micrognathism and Pierre Robin Sequence
- Multicystic Dysplastic Kidney Disease
- Omphalocele
- Ovarian Cysts
- Polycystic Kidney Disease
- Twin-to-Twin Transfusion Syndrome
- Prune Belly Syndrome
- Spina Bifida
- Meet Our Team
- Research
- Success Stories
- Licensure, Accreditations and Memberships
- Resources
- Contact Us